Quetmolimab: A Deep Dive into KANAb 001 and E-6011 The compound, E-6011, shows a novel immunotherapy aimed at PD-1. Early study data from the two initiatives, KANAb 001 and E-6011, demonstrate significant effects in https://bookmark-dofollow.com/story28271644/text